InDevR announced today that it will follow proof of concept development for the new VaxArray potency tests for measles (M) and rubella vaccines sponsored by the Bill & Melinda Gates Foundation. The long-term goal is to create in vitro measles and rubella potential analyzes to deliver high quality MR vaccines to the market with faster and lower production costs. The project will benefit from the multi-storey VaxArray platform, which was developed and approved for the first time to test the more effective potential of influenza vaccines. Accurate measurement of vaccine "strength" is important because the vaccine manufacturer allows it to pack the correct amount of the correct component. Overfilling may result in a sub-strong vaccine that does not protect the patient, and overfilling may cause a safety problem – in both cases an unacceptable product is produced.
Measles and rubella (ında German measles ”) are highly contagious diseases with significant health effects worldwide. According to the Measles and Rubella Initiative, half a million children die from measles and related complications every year before 2000. This disease can be prevented by well proven vaccines. It would be useful to accelerate the vaccine production process to bring the vaccine to everyone in need around the world.
Dr. Novartis Vaccines of the former Global Global Politics . Measles and rubella vaccines will continue to be the cornerstones of pediatric immunization programs in both developed and developing countries, Kla says Klaus Stohr. VaxArray may have the potential to reduce production costs. This is an important contribution to increasing the availability of these life-saving vaccines worldwide. "
Time-consuming biological tests, such as the tissue culture infectious dose (TCID50), which is 1-2 weeks old, are currently used to measure the potential for MR vaccines. The VaxArray platform offers 2-hour analysis to monitor the potential throughout the vaccine production process, which can reduce the production process for weeks and possibly allocate the time required to deliver the vaccine to the market. For example, the measles and rubella TCID50 specifications for vaccine release are currently 3000 and 1000 infectious particles / doses, respectively. A more accurate force experiment for each of these live attenuated virus antigens will minimize risks and reduce expensive lot rejections.
Kathry Rowlen, CEO of InDevR, is excited to partner with the Bill & Melinda Gates Foundation. The sponsorship of this project is a further confirmation of the VaxArray platform's potential to improve the vaccine potential test.
Posted in: Device / Technology News | Disease / Infection News